Engineering of Botulinum Neurotoxins for Biomedical Applications
AbstractBotulinum neurotoxins (BoNTs) have been used as therapeutic agents in the clinical treatment of a wide array of neuromuscular and autonomic neuronal transmission disorders. These toxins contain three functional domains that mediate highly specific neuronal cell binding, internalization and cytosolic delivery of proteolytic enzymes that cleave proteins integral to the exocytosis of neurotransmitters. The exceptional cellular specificity, potency and persistence within the neuron that make BoNTs such effective toxins, also make them attractive models for derivatives that have modified properties that could potentially expand their therapeutic repertoire. Advances in molecular biology techniques and rapid DNA synthesis have allowed a wide variety of novel BoNTs with alternative functions to be assessed as potential new classes of therapeutic drugs. This review examines how the BoNTs have been engineered in an effort to produce new classes of therapeutic molecules to address a wide array of disorders. View Full-Text
Share & Cite This Article
Webb, R.P. Engineering of Botulinum Neurotoxins for Biomedical Applications. Toxins 2018, 10, 231.
Webb RP. Engineering of Botulinum Neurotoxins for Biomedical Applications. Toxins. 2018; 10(6):231.Chicago/Turabian Style
Webb, Robert P. 2018. "Engineering of Botulinum Neurotoxins for Biomedical Applications." Toxins 10, no. 6: 231.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.